LXR β Antibodies

Santa Cruz Biotechnology features a diverse variety of LXR β monoclonal antibodies for advanced research in lipid metabolism and nuclear receptor signaling. LXR β monoclonal antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). LXR β, or Liver X Receptor beta, plays a crucial role in regulating cholesterol homeostasis and fatty acid metabolism, making it an important target for studies related to metabolic disorders and cardiovascular diseases. By modulating the expression of genes involved in lipid metabolism, LXR β influences cellular responses to sterols and oxysterols, highlighting its significance in maintaining cellular health and function. Understanding the mechanisms of LXR β can provide insights into therapeutic strategies for metabolic diseases. Research focused on LXR β has revealed its potential as a therapeutic target for conditions such as atherosclerosis, diabetes, and inflammatory disorders. Investigating LXR β signaling pathways has enhanced our understanding of lipid homeostasis and its impact on human health. Santa Cruz Biotechnology monoclonal antibodies support researchers in advancing scientific knowledge of metabolic regulation and disease treatment strategies.